<DOC>
	<DOCNO>NCT00097695</DOCNO>
	<brief_summary>The purpose study assess efficacy safety Icatibant , bradykinin antagonist treatment acute cutaneous and/or abdominal attack patient hereditary angioedema ( HAE ) .</brief_summary>
	<brief_title>Subcutaneous Treatment With Icatibant Acute Attacks Hereditary Angioedema</brief_title>
	<detailed_description>This Phase II/III study consist two part : A controlled phase An Open label extension ( OLE ) phase . The controlled phase describe double blind part study intend evaluate efficacy icatibant decreasing time onset symptom relief compare placebo first treat cutaneous and/or abdominal attack randomise patient . Patients experience laryngeal attack randomise , treat open label icatibant accord control phase procedure assessment . The outcome group report descriptively . After treatment first attack controlled phase , patient eligible enter OLE phase . In OLE phase , patient experience angioedema attack severe enough warrant treatment treat s.c. icatibant appropriate end study.The OLE phase become modified open label extension 56 patient randomise last randomised patient conclude double-blind phase . The modified open label extension period permit treatment patient screen found eligible experience angioedema attack , attack severe enough merit treatment double blind phase still ongoing .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<criteria>Age 18 year ; Documented diagnosis HAE Type I II ( confirm complement 1 esterase inhibitor [ C1INH ] deficiency ) ; Current edema cutaneous , abdominal and/or laryngeal area ; Current edema moderate severe accord investigator 's Symptom Score . Diagnosis angioedema HAE , example , acquire angioedema ( AAE ) ; Participation clinical trial another investigational medicinal product ( IMP ) within past month ; Treatment pain medication since onset current edema attack ; Treatment replacement therapy , include C1INH product ( e.g . human C1INH preparation ) , less 3 day onset current edema attack ; Treatment ACE inhibitor ( e.g . Lotensin , Prinivil , Accupril ) ; Evidence severe , symptomatic coronary artery disease base medical history screen examination ; Serious concomitant illnesses physician considers contraindication participation trial ; Pregnancy and/or breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Hereditary Angioedema</keyword>
	<keyword>C1 inhibitor deficiency</keyword>
	<keyword>HAE</keyword>
	<keyword>Icatibant</keyword>
	<keyword>Bradykinin antagonist</keyword>
	<keyword>acute attack</keyword>
	<keyword>subcutaneous</keyword>
</DOC>